Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Fineline Cube Mar 13, 2026
Company Deals

APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio

Fineline Cube Mar 13, 2026
Company Deals

WuXi Biologics Partners with Earendil Labs – Integrated CDMO Services for Bispecific Antibodies and ADCs Targeting Autoimmune and Oncology Indications

Fineline Cube Mar 13, 2026
Company Deals

Everest Medicines Reports Positive Phase IIa Data for VIS-101 – Dual VEGF-A/Ang-2 Inhibitor Shows Best-in-Class Potential in wAMD

Fineline Cube Mar 13, 2026
Company Deals

Luye Pharma Signs Strategic Partnership with Sinopharm – Mimeixin Distribution Deal Targets China’s Severe Pain Market

Fineline Cube Mar 13, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Fineline Cube Mar 13, 2026
Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Fineline Cube Mar 13, 2026
Company Deals Digital

ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development

Fineline Cube May 12, 2023

ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic...

Drug Legal / IP

CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China

Fineline Cube May 11, 2023

The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...

Company Drug

Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...

Company Drug

Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its...

Company Drug

CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo

Fineline Cube May 11, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for...

Company Drug

Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults

Fineline Cube May 11, 2023

China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing...

Policy / Regulatory

Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion

Fineline Cube May 11, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification outlining key tasks for the...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer

Fineline Cube May 11, 2023

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that...

Company Drug

Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC

Fineline Cube May 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB)...

Company Drug

Sichuan Kelun Pharmaceutical’s A166 Anti-HER2 ADC NDA Accepted for Review by NMPA

Fineline Cube May 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has announced that the...

Company Deals

Suzhou Porton Biologics and Synbio Technologies Partner to Advance Cell and Gene Therapy in China

Fineline Cube May 10, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

Mabwell Bioscience’s 9MW3911 Receives NMPA Approval for Clinical Trial in Advanced Tumors

Fineline Cube May 10, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Company Drug

Akeso Biopharma Initiates Phase III Study for Ivonescimab in Non-Small Cell Lung Cancer

Fineline Cube May 10, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the initiation of a Phase III clinical study...

Company Drug

Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights

Fineline Cube May 10, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the...

Company Drug

Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients

Fineline Cube May 10, 2023

Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has announced receiving market approval...

Company Drug

Jiangsu Nhwa Pharmaceutical Receives NMPA Approval for Olinvyk (Oliceridine) Injection

Fineline Cube May 10, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a China-based pharmaceutical company, has announced that it...

Company Drug

Innovent Biologics’ Tyvyt Secures NMPA Approval for EGFR-Mutated NSCLC Treatment

Fineline Cube May 10, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

China’s NHC Releases Draft Guidelines for Somatic Cell Clinical Research, Seeks Public Input

Fineline Cube May 10, 2023

The National Health Commission (NHC) has released the “Somatic Cell Clinical Research Guidelines (draft proposal)”...

Company Deals

Zion Pharma’s ZN-A-1041 Acquired by Roche for Global Development and Commercialization

Fineline Cube May 9, 2023

China-based Zion Pharma Ltd, a biotechnology company specializing in the development of brain-penetrable compounds, has...

Company Drug

Grand Pharmaceutical Group Files NDA for Ophthalmic Analgesic APP13007 with US FDA

Fineline Cube May 9, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the filing of a New Drug...

Posts pagination

1 … 495 496 497 … 634

Recent updates

  • Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market
  • Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing
  • CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces
  • Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
  • APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kintor Pharmaceutical Partners with Fonow Medicine – KT-939 Cosmetic Collaboration Targets China Whitening and Melasma Market

Company Drug

Sino Biopharm’s TQB3454 Hits Phase III Endpoints in IDH1+ Biliary Tract Cancer – China’s First IDH1 Inhibitor Poised for NDA Filing

Company Drug

CMS Launches Opzelura Nationwide – First Topical JAK Inhibitor for Vitiligo Reaches 1,300+ Pharmacies Across 30 Chinese Provinces

Company Drug

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.